OraSure Technologies Inc
Suletud
SektorTervishoid
3.06 -1.92
Ülevaade
Aktsiahinna muutus
24h
Min
3.05
Max
3.09
Sissetulek | -2.3M -16M |
|---|---|
Müük | -322K 27M |
Kasumimarginaal | -59.946 |
Töötajad | 500 |
EBITDA | -7.8M -19M |
Järgmine tulemuste avaldamine | 4. aug 2026 |
|---|
Turukapital | 11M 212M |
|---|---|
Eelmine avamishind | 4.98 |
Eelmine sulgemishind | 3.06 |
Uudiste sentiment
By Acuity
50%
50%
153 / 347 Pingereas Healthcare
Tehniline skoor
By Trading Central
Kindlus
Strong Bearish Evidence
OraSure Technologies Inc Graafik
Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.
Seotud uudised
Võrdlus sarnastega
Hinnamuutus
OraSure Technologies Inc Prognoos
Sentiment
By Acuity
153 / 347 Pingereas Tervishoid
Uudiste sentiment
Neutral
Volatiilsus
Alla keskmise
Uudismaht (RCV)
Alla keskmise
Finantsandmed
Müügi- ja halduskulud
Tegevuskulud
Maksueelne kasum
Müük
Müügikulu
Brutokasum müügist
Intressikulud võla pealt
EBITDA
Ärikasum
$
Ettevõttest OraSure Technologies Inc
OraSure Technologies, Inc., together with its subsidiaries, provides point-of-care and home diagnostic tests, specimen collection devices, and microbiome laboratory and analytical services in the United States, Europe, and internationally. The company's products include InteliSwab COVID-19 rapid test, InteliSwab COVID-19 rapid test pro, InteliSwab COVID-19 rapid test rx, OraQuick Rapid HIV test, OraQuick In-Home HIV test, OraQuick HIV self-test, OraQuick HCV rapid antibody test, OraQuick Ebola rapid antigen test, OraSure oral fluid collection device used in conjunction with screening and confirmatory tests for HIV-1 antibodies; Intercept drug testing systems; immunoassay tests and reagents; and Q.E.D. saliva alcohol test. It also offers genomic products under the Oragene and ORAcollect brands for collecting genetic material from human saliva; Colli-Pee collection devices for the volumetric collection of void urine samples; and microbiome laboratory testing and analytical services. In addition, the company provides microbiome products, such as OMNIgene GUT for self-collecting microbial DNA from feces or stool samples for gut microbiome profiling; OMNIgene GUT DNA and RNA collection devices; and OMNIgene GUT Dx collection device for collection of human fecal samples and the stabilization of DNA from the bacterial community. Additionally, it provides other diagnostic products, such as immunoassays and other in vitro diagnostic tests. The company markets its products to clinical laboratories, hospitals, clinics, community-based organizations and other public health organizations, distributors, government agencies, physicians' offices, commercial and industrial entities, disease risk management, diagnostics, pharmaceutical, biotech, nutrition, companion animal, and environmental markets. OraSure Technologies, Inc. was incorporated in 2000 and is based in Bethlehem, Pennsylvania.
